SCHEMBL1024956

SCHEMBL1024956

OCc1cccc(Nc2nc(Cl)ncc2Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.55
JAK2 O60674 3/20 0.48
JAK3 P52333 3/20 0.48
ABL1 P00519 3/20 0.48
TOP2A P11388 1/20 0.47
TOP2B Q02880 1/20 0.47
NTRK1 P04629 1/20 0.46
FLT1 P17948 1/20 0.45
FLT4 P35916 1/20 0.45
KDR P35968 1/20 0.45
BCL6 P41182 2/20 0.44
EGFR P00533 3/20 0.44
PDGFRB P09619 1/20 0.44
KIT P10721 1/20 0.44
FGFR1 P11362 1/20 0.44
SRC P12931 1/20 0.44
PDGFRA P16234 1/20 0.44
MAPK14 Q16539 1/20 0.44
ABCG2 Q9UNQ0 3/20 0.44
CSNK2A1 P68400 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1025775 0.89 CTSC (0.44) SYKJAK2JAK3ABL1NTRK1
SCHEMBL654717 0.86 SYK (0.74) SYKJAK2JAK3ABL1TOP2A
SCHEMBL12651575 0.84 SYK (0.60) SYKJAK2JAK3ABL1NTRK1
SCHEMBL2062260 0.83 BCL6 (0.42) JAK2JAK3BCL6EGFRCTSC
SCHEMBL1024077 0.82 SYK (0.65) SYKJAK2JAK3ABL1NTRK1
SCHEMBL1025214 0.82 SYK (0.65) SYKJAK2JAK3ABL1NTRK1
SCHEMBL1026771 0.82 CTSC (0.47) SYKJAK2JAK3NTRK1BCL6
SCHEMBL2062217 0.81 MEN1 (0.45) SYKJAK2JAK3BCL6EGFR
SCHEMBL1025790 0.80 BCL6 (0.45) JAK2JAK3NTRK1KDRBCL6
SCHEMBL4175833 0.80 BCL6 (0.56) SYKJAK2JAK3ABL1BCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK SYK 46/4885JAK2 1/4885JAK3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.